// App-Quantinova.ai

905 : Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Researchers

Presenter

  • Tetsuzo Tauchi

Principal Investigators

  • Seiichiro Katagiri

  • Seiichi Okabe

  • Yuko Tanaka

  • Kazuma Ohyashiki

Medical Centers

  • Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Cluster of Differentiation 34

  • Interleukin-2

Drug/Treatment

  • Ponatinib

  • L-Tyrosine

  • BBI-608

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved